Erlotinib, a type of targeted therapy for the treatment of cancer, is a tyrosine Kinase inhibitor – working by blocking the kinase activity of a protein – called as Epidermal Growth Factor Receptor or EGFR. This is involved in cell growth and survival.
Epidermal Growth Factor Receptor is found on the surface of normal and cancerous cells. Even the normal version of the EGFR protein can contribute to the development of cancer. In other cases, mutations can occur in the EGFR protein – that may enable cancer cells to growth, divide, and spread faster.
Erlotinib is used to treat pancreatic cancer and non-small cell lung cancer (NSCLC).
Keep in mind, it is only used to treat cases of NSCLC that have specific mutations in their EGRF protein – exon 19 deletions or exon 21 substitution mutations.
This is an FDA approved drug – available under the brand name Tarceva.
How Does Erlotinib 100mg Tablet Work?
Erlotinib 100mg is an oral targeted therapy used to treat certain types of non-small cell lung cancer (NSCLC), depending on the cancer’s characteristics and treatment plan. This drug belongs to a class of medicines called epidermal growth factor receptor (EGFR) inhibitors, which work by blocking signals that encourage cancer cells to grow and multiply.
Erlotinib inhibits the activity of the EGFR protein, which plays an important role in cell growth and division. By blocking this signaling pathway, it can help slow cancer progression in patients whose tumors are suitable for this treatment.
By inhibiting EGFR signaling, Erlotinib or Tarceva can help restrict the growth and multiplication of certain cancer cells. Its effects may also involve healthy tissues, potentially causing side effects such as skin rash, diarrhea, loss of appetite and fatigue.
This drug is classified as a targeted anticancer medicine known as an EGFR tyrosine kinase inhibitor. Treatment suitability, dosage and duration depend on the cancer type, EGFR mutation status, previous treatments and the patient’s overall health.
Dosage of Erlotinib 100 mg, 30 Tablets :
Erlotinib 100mg is an oral targeted cancer medicine classified as an epidermal growth factor receptor (EGFR) inhibitor. It is used to treat certain types of non-small cell lung cancer, depending on the s EGFR mutation status and treatment indication of the tumor. It must be taken according to an oncologist’s prescription.
This tablet form is taken by mouth, generally once daily on an empty stomach, at least one hour before or two hours after food.
The dosage depends on the cancer type, EGFR mutation status, treatment indication, overall health and response to therapy. The prescribed dose must be followed precisely. For certain indications, erlotinib is prescribed at a daily dose of 150 mg for non-small cell lung cancer or 100 mg for pancreatic cancer in combination with gemcitabine.
The appropriate dose depends on the approved treatment regimen. The oncologist may reduce or temporarily interrupt treatment depending on side effects, liver function, other medicines and the patient’s tolerance. Regular medical monitoring is essential during therapy.
Benefits of Using Erlotinib 100 mg, 30 Tablets :
Erlotinib 100mg is an oral targeted cancer medicine used to treat certain types of non-small cell lung cancer (NSCLC) with specific epidermal growth factor receptor (EGFR) mutations. It belongs to a class of medicines called EGFR tyrosine kinase inhibitors, which block signals that help cancer cells grow and multiply.
Erlotinib may be prescribed for eligible patients with locally advanced or metastatic NSCLC, depending on the tumor’s molecular characteristics and previous treatment. Its suitability depends on the confirmed EGFR mutation status, cancer stage, and the treating oncologist’s assessment.
This drug inhibits EGFR tyrosine kinase activity, helping interrupt signaling pathways that can promote the growth and division of susceptible cancer cells.
This medicine may be used as targeted treatment for eligible patients with advanced or metastatic NSCLC carrying specific activating EGFR mutations.
Erlotinib may help slow cancer progression in suitable patients, although treatment response varies according to tumor biology and individual circumstances.
Erlotinib is available as an oral tablet, allowing treatment at home when prescribed, with appropriate medical supervision and follow-up.
Erlotinib is also used with gemcitabine to treat locally advanced, unresectable, or metastatic pancreatic cancer, according to the approved indication.
Side Effects of Tarceva 100mg – 30 Tablets :
Treatment with Erlotinib may cause mild to serious side effects depending on individual health and treatment response. Commonly reported side effects include:
- Nausea, vomiting, and diarrhea
- Fatigue, weakness, and loss of appetite
- Acne-like skin rash and dry skin
- Abdominal pain and indigestion
- Mouth sores and eye irritation
- Cough and shortness of breath
This drug may increase the risk of infections, liver problems, and, rarely, serious lung inflammation or gastrointestinal perforation. Contact a healthcare professional promptly if you experience severe breathing difficulties, persistent diarrhea, significant abdominal pain, yellowing of the skin or eyes, or unusual bleeding.
Regular monitoring of liver function and other relevant health parameters is important during treatment. Take this medicine only under specialist supervision.
Conclusion :
Erlotinib 100mg or Tarceva tablet is a prescription targeted therapy classified as an epidermal growth factor receptor (EGFR) inhibitor, used to treat certain types of non-small cell lung cancer. Treatment suitability and dosage depend on the cancer type and individual patient factors.
Important Medical Warning :
Use any other product here strictly according to your doctor’s prescription. Follow your healthcare professional’s instructions regarding dosage, administration, and treatment duration. Do not self-medicate, change the dose, or discontinue treatment without consulting your doctor. This medication must be administered by qualified healthcare professionals.
Reviews
There are no reviews yet.